4P-Pharma Welcomes Marina Vasiliou, Christian Bechon, and Alain Sainsot as Independent Members of Its Board
10.9.2024 07:30:00 CEST | Business Wire | Press release
Marina Vasiliou, Biogen France President and Managing Director Christian Bechon, Senior Partner chez Isalys Augmented Management Alain Sainsot, GTP Bioways founder and President
4P-Pharma, a clinical-stage startup based in Lille that develops disease-modifying therapies for untreated serious diseases, is delighted to welcome Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent and non-executive members to its Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909483462/en/
4P-Pharma welcomes Marina Vasiliou, Christian Bechon and Alain Sainsot as independent members of its board (Photo: Business Wire)
These novel additions will strengthen 4P-Pharma's goal to become a commercial-stage, fully integrated biopharma company covering the whole value chain from discovery to commercialization.
Revital Rattenbach, CEO of 4P-Pharma, says: "We proudly welcome three exceptional leaders to our Board of Directors. Each new member brings substantial expertise and proven leadership abilities, which are crucial to 4P-Pharma during this period of significant company growth."
Concerning the new members:
- Marina Vasiliou, Biogen France President and Managing Director
Marina Vasiliou has been serving as the President and Managing Director of Biogen France since 2021. Biogen is a pioneering international biotechnology company at the forefront of science and innovation, developing tomorrow's medicines in neurology, neuropsychiatry, immunology, and rare diseases. Marina Vasiliou's insights are essential in navigating regulatory requirements and market access strategies. She has experience managing commercial launches and reimbursement in different international settings, including the US, mainly in chronic and rare disease therapies.
"Contributing with my global commercial leadership expertise to supporting 4P-Pharma ambition fills me with great satisfaction. I fully believe in the company's mission to enhance patients' access to first-in-class therapies for untreated serious diseases. I trust the commitment and innovation of 4P-Pharma's CEO and executive team, and I am thrilled to work with them on a diverse Board of Directors," declared Marina Vasiliou.
- Christian Bechon, Senior Partner chez Isalys Augmented Management
Christian Bechon is the former Chairman and CEO of LFB Group. Under his leadership, LFB Group has transformed from a French leader in plasma cell fractionation to an internationally recognized player with a global footprint.
"4P-Pharma is a promising French biotech company that prioritizes patients' needs. The company's main objective is to contribute to healthcare innovation in France and Europe while maintaining its independence. I am privileged to be a part of this entrepreneurial journey and provide valuable guidance to the leadership team to catalyze 4P-Pharma’s next wave of growth," said Christian Bechon.
- Alain Sainsot, GTP Bioways founder and President
Alain Sainsot, Founder and President of GTP Bioways, has served as Senior Director of Group Operations and Logistics for leading pharmaceutical companies like Pierre Fabre. He is a serial industrial entrepreneur who created two fast-growing CDMOs, Amatsi-group (acquired) and GTP-Bioways. He brings extensive experience in the industrial anchor of drug development to 4P-Pharma.
"It is an honor for me to join 4P-Pharma in their mission to develop innovative drugs for patients. I am confident in Revital Rattenbach's dedication and her leadership team's commitment to providing first-in-class treatments to patients. I look forward to joining forces and implementing the highest quality standards to industrialize 4P-Pharma's promising therapeutic pipeline further," stated Alain Sainsot.
Concerning the Board of Directors of 4P-Pharma
These new members reinforce the existing 4P-Pharma Board of Directors, which is composed of robust and well-known life science experts.
Their comprehensive industry knowledge and extensive network strengthen the company's credibility and strategic vision in the biotech and pharma sectors.
Jean Pierre Lehner,Chairman of the 4P-Pharma Board of Directors, concluded: "I am thrilled by Marina Vasiliou, Christian Bechon, and Alain Sainsot's enthusiasm for joining our Board. Their combined expertise will accelerate our mission and strengthen our ability to bring innovative therapies to those in need."
About 4P-Pharma
Founded in 2014, 4P-Pharma is a clinical-stage biotechnology company based in Lille dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Our goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property. The company is headquartered in Lille and Paris and has over 20 employees.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
X: https://twitter.com/4Moving_Biotech
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909483462/en/
Contacts
Press Contact
Press Contact
Communication – media Relations
Emmanuel Dadjé - Communication Manager
Emmanuel.dadje@4P-Pharma.com
Tel : +33 6 30 06 12 13
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom